RankingsPricing
  1. US-listed companies
  2. Ultragenyx Pharmaceutical Inc.
  3. Financials
  4. Common stock and paid-in capital

Ultragenyx Pharmaceutical Inc.RARE

Market cap
$3.1B
P/E ratio
SummaryFinancials
Period EndCommon stock and paid-in capital (Million USD)YoY (%)
Dec 31, 20244,213+15.03%
Dec 31, 20233,662+16.63%
Dec 31, 20223,140+4.75%
Dec 31, 20212,998+8.09%
Dec 31, 20202,773+32.89%
Dec 31, 20192,087+27.26%
Dec 31, 20181,640+34.21%
Dec 31, 20171,222+21.74%
Dec 31, 20161,004+22.90%
Dec 31, 2015817+151.92%
Dec 31, 2014324

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)